Kinamycin B | CAS#35303-13-0 | anticancer

MedKoo Cat#: 558525 | Name: Kinamycin B

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Kinamycin B is an antibacterial agent that is used for anticancer purposes.

Chemical Structure

Kinamycin B

CAS#35303-13-0

Theoretical Analysis

MedKoo Cat#: 558525

Name: Kinamycin B

CAS#: 35303-13-0

Chemical Formula: C20H16N2O8

Exact Mass: 412.0900

Molecular Weight: 412.35

Elemental Analysis: C, 58.26; H, 3.91; N, 6.79; O, 31.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Kinamycin B; Kinamycin-B; KinamycinB;

IUPAC/Chemical Name

5H-Benzo(b)carbazole-5-carbonitrile, 3-(acetyloxy)-1,2,3,4,6,11-hexahydro- 1,2,4,7-tetrahydroxy-3-methyl-6,11-dioxo-

InChi Key

VTBQTYQHTVTELM-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H16N2O8/c1-7(23)30-20(2)18(28)14-12(17(27)19(20)29)11-13(22(14)6-21)16(26)10-8(15(11)25)4-3-5-9(10)24/h3-5,17-19,24,27-29H,1-2H3

SMILES Code

N#CN1C(C(C2=C(O)C=CC=C23)=O)=C(C4=C1C(O)C(OC(C)=O)(C)C(O)C4O)C3=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 412.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang B, Ren J, Li L, Guo F, Pan G, Ai G, Aigle B, Fan K, Yang K. Kinamycin biosynthesis employs a conserved pair of oxidases for B-ring contraction. Chem Commun (Camb). 2015 May 25;51(42):8845-8. doi: 10.1039/c5cc01986a. PubMed PMID: 25920893. 2: Woo CM, Gholap SL, Lu L, Kaneko M, Li Z, Ravikumar PC, Herzon SB. Development of enantioselective synthetic routes to (-)-kinamycin F and (-)-lomaiviticin aglycon. J Am Chem Soc. 2012 Oct 17;134(41):17262-73. doi: 10.1021/ja307497h. Epub 2012 Oct 3. PubMed PMID: 23030272; PubMed Central PMCID: PMC3505684. 3: Gould SJ, Melville CR, Cone MC, Chen J, Carney JR. Kinamycin Biosynthesis. Synthesis, Isolation, and Incorporation of Stealthin C, an Aminobenzo[b]fluorene. J Org Chem. 1997 Jan 24;62(2):320-324. PubMed PMID: 11671405. 4: Kumamoto T. [Synthetic studies on kinamycin antibiotics]. Yakugaku Zasshi. 2010 Nov;130(11):1535-41. Review. Japanese. PubMed PMID: 21048414. 5: Omura S, Nakagawa A, Yamada H, Hata T, Furusaki A. Structures and biological properties of Kinamycin A, B, C, and D. Chem Pharm Bull (Tokyo). 1973 May;21(5):931-40. PubMed PMID: 4727361. 6: Seaton PJ, Gould SJ. New products related to kinamycin from Streptomyces murayamaensis. II. Structures of pre-kinamycin, keto-anhydrokinamycin, and kinamycins E and F. J Antibiot (Tokyo). 1989 Feb;42(2):189-97. PubMed PMID: 2925510. 7: Hasinoff BB, Wu X, Yalowich JC, Goodfellow V, Laufer RS, Adedayo O, Dmitrienko GI. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects. Anticancer Drugs. 2006 Aug;17(7):825-37. PubMed PMID: 16926632. 8: Colis LC, Woo CM, Hegan DC, Li Z, Glazer PM, Herzon SB. The cytotoxicity of (-)-lomaiviticin A arises from induction of double-strand breaks in DNA. Nat Chem. 2014 Jun;6(6):504-10. doi: 10.1038/nchem.1944. Epub 2014 May 11. PubMed PMID: 24848236; PubMed Central PMCID: PMC4090708. 9: Woo CM, Gholap SL, Herzon SB. Insights into lomaiviticin biosynthesis. Isolation and structure elucidation of (-)-homoseongomycin. J Nat Prod. 2013 Jul 26;76(7):1238-41. doi: 10.1021/np400355h. Epub 2013 Jun 26. PubMed PMID: 23803003. 10: Zeng W, Eric Ballard T, Tkachenko AG, Burns VA, Feldheim DL, Melander C. Mimicking the biological activity of diazobenzo[b]fluorene natural products with electronically tuned diazofluorene analogs. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5148-51. Epub 2006 Jul 25. PubMed PMID: 16870443. 11: Pan G, Gao X, Fan K, Liu J, Meng B, Gao J, Wang B, Zhang C, Han H, Ai G, Chen Y, Wu D, Liu ZJ, Yang K. Structure and Function of a C-C Bond Cleaving Oxygenase in Atypical Angucycline Biosynthesis. ACS Chem Biol. 2017 Jan 20;12(1):142-152. doi: 10.1021/acschembio.6b00621. Epub 2016 Nov 30. PubMed PMID: 28103689.

View History

3-Acetylbenzophenone

MedKoo CAT#: 531837

CAS#: 66067-44-5